October 11, 2018, at 1:00 PM EST
More and more OTC drug and dietary supplement companies are contracting out manufacturing, packaging, laboratory testing, and distribution services. This requires a full understanding of how those contract services are being conducted in order to have complete confidence that their products are meeting quality specifications and regulatory requirements. In addition in the past several years, the FDA has focused more intensely on such companies that they refer to as “own label distributors” (“OLDs”). The result has been an escalating number of FDA inspections, Form 483 inspection observations, and warning letters.
With such increasing FDA enforcement activity, it is imperative that those in responsible positions in OLDs gain a full understanding of FDA’s requirements for “knowing what and how these [contracted] activities are performed so that you can make decisions — whether to approve and release the products for distribution”. This also means that you are “responsible for ensuring that the product is not adulterated for failure to comply with CGMP requirements, regardless of who actually performs the CGMP operations”.
Learn more about your “OLD” responsibilities and how to document that you are meeting them. Join EAS Independent Consultant, Bruce Elsner for this informative webinar. Reserve your seat today!
This webinar will include the following topics:
- FDA’s Explanation of the Responsibilities of an “Own Label Distributor
- How To Meet Your “OLD” Responsibilities
- Qualifying Contract Service Providers
- Establishing a Quality Agreement With a Contract Service Provider
- Responsibilities of an “OLD’s” Quality Unit
- Key SOPs/Documents & Recommended Content
- On-Going Monitoring of a Contract Manufacturer/Packager
Time for an interactive Q&A period will be provided at the end of the presentation.
About the presenter
EAS Independent Consultant, Bruce Elsner, has over 28 years of experience working in FDA regulated fortune 250 companies manufacturing and packaging drug, medical device, and cosmetic products. His responsibilities have included laboratory management, process control and improvement, pilot plant management, plant quality assurance management and quality systems improvement across multiple manufacturing and research facilities. He has been consulting for OTC drug and dietary supplement companies for more than 22 years in the areas cGMP compliance auditing and quality systems improvement. His experience also includes training drug and dietary supplement industry personnel in cGMP requirements, assisting in improving their levels of compliance with those regulations and helping them respond to complex issues arising from FDA inspection observations, warning letters and consent decrees.